The effect of calcitonin gene-related peptide monoclonal antibodies on restless legs syndrome in patients with migraine.

ABSTRACT:

Background

Calcitonin gene-related peptide monoclonal antibody (CGRP mAb) effects on restless legs syndrome (RLS) are unclear.

Methods

Fifteen migraine patients (aged 49.1 ± 5.8 years; 14 women) with concomitant RLS who received CGRP mAbs (2 erenumab, 3 galcanezumab, and 10 fremanezumab) were retrospectively studied. Number of monthly migraine days (MMDs) was obtained from headache diaries. The primary outcome is changes in RLS severity as assessed by the International RLS Group Rating Scale (IRLS). Headache-related disability was assessed using the Migraine Disability Assessment (MIDAS). The severity of headache and RLS was rated using the Patient Global Impression of Change (PGIC) scale. Central sensitization was evaluated with the Central Sensitization Inventory (CSI).

SUBMITTER: Suzuki K 

PROVIDER: S-EPMC11837639 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature